BioBusiness

Articles

Merck is acquiring the Yale-spinout, which develops direct DNA modification-enabled cancer treatments. 

Modifi Biosciences Acquired by Merck

The merger will create a specialty company, REGiMMUNE/Kiji TX, for regulatory T cells.

REGiMMUNE and Kiji Therapeutics to Merge

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Vectura’s expertise in the field includes formulation and device development for dry powder inhalers and pressurized metered dose inhalers, among other products and services.

Phillips Medisize Expands Inhalation Drug Delivery Capabilities with Acquisition of Vectura

Feliza Mirasol is the science editor for 

With the completion of its acquisition of Morphic, Lilly expands its immunology pipeline to include Morphic's oral integrin therapies to address inflammatory bowel disease.

Lilly Completes $3.2 Billion Acquisition of Morphic, Boosting Its IBD Pipeline

Under a deal worth potentially up to $1.3 billion, Merck, known as MSD outside of the United States and Canada, will acquire CN201, a next-generation bispecific antibody, from Curon Biopharmaceutical. 

Merck Plans to Acquire Investigational Bispecific Antibody from Curon Biopharmaceutical in $1.3 Billion Deal

With this acquisition, AbbVie gains Cerevel’s clinical-stage assets that complement AbbVie's emerging neuroscience pipeline as well as branded products for treating psychiatric disorders, migraine, and Parkinson's disease.

AbbVie Completes $8.7 Billion Acquisition of Cerevel Therapeutics to Boost Neurological Pipeline

Editor of Pharmaceutical Technology Europe

The addition of BIOVECTRA’s biologics capabilities to accelerate drug development and manufacturing will allow Agilent to expand its end-to-end offerings for biopharma services. 

Agilent Expands Biopharma Offerings with BIOVECTRA Acquisition

The acquisition adds a Phase III therapeutic peptide candidate to AstraZeneca’s late-stage pipeline for rare diseases.

AstraZeneca Strengthens Rare Disease Portfolio with Amolyt Pharma Acquisition

The acquisition of EyeBio adds a late-phase antibody drug candidate for diabetic macular edema and neovascular age-related macular degeneration to Merck’s pipeline. 

Merck Completes EyeBio Acquisition, Strengthens Eye Disease Portfolio

The acquisition adds NM26, a Phase II-ready bispecific antibody for treating atopic dermatitis, to Johnson & Johnson’s immune-mediated and inflammatory disease portfolio.

Mergers and Acquisitions